January 21, 2021 5:19pm
As I stated last night, wait for the reverses, they came today
Numbers based facts speak better then opinion as I see answers in numbers
Pre-open indication: 11 HITs and 1 MISS
Are we here to make money or see share pricing erode as earnings LPS (loss-per-share) season is about to begin?
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!
The Dow closed DOWN -12.37 points (-0.04%); the S&P closed UP +1.22 points (-0.03%) while the Nasdaq closed UP +73.67 points (+0.55%)
Henry’omics:
The Dow and S&P traded down while the and S&P and Nasdaq “shimmied” to a high
Thursday’s action came after a better-than-expected reading on jobless claims. First-time claims for unemployment insurance totaled 900,000 for the week ended Jan. 16, lower than an estimate of 925,000.
The S&P 500 has gained 2.8% so far in 2021, and the Nasdaq has climbed nearly 5% during the same period.
Sentiment and COVID-19 infections:
Well said, “We see the pace of vaccinations as a key driver of equities through 2021, similar to how shifts in mobility and COVID-19 cases drove equities in 2020,” Keith Parker, head of equity strategy at UBS, said in a note”. “Removing bottlenecks for administering doses would present an upside case near-term.”
Infection cases <Million>: never to forget …
- Thursday 24.45 M cases,
- Thursday’s death rate totaled 406,536 <Johns Hopkins University>
This a.m.’s post, “snails crawl at a slow pace; will there be a slime trail? As markets set sector’s share pricing.” … https://www.regmedinvestors.com/articles/11730
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …
- Thursday opened negative at 2/31 and 1 flat, stayed negative at the mid-day to 8/26 and 1 flat, closing negative at 9/25 and 1 acquired;
- Wednesday opened negative at 13/18 and 4 flats, flipped neutral at the mid-day to 17/17 and 1 flat, closing negative at 16/18 and 1 acquired;
- Tuesday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 20/13 and 2 flats, closing positive at 18/14, 2 flats and 1 acquired;
- Monday was holiday
Pre-open indication:
- 11 HITs <SELL into offering: Editas Medicine (EDIT -$7.97), Caladrius Biosciences (CLBS -$0.39); SELL into Strength: Fate Therapeutics (FATE -$9.34), bluebird bio (BLUE -$1.04), CRISPR Therapeutics (CRSP -$4.67); Intellia Therapeutics (NTLA -$7.97), Pluristem (PSTI +$0.54), Global Blood therapeutics (GBT -$0.37), Homology Medicine (FIXX -$0.71), Ionis Pharmaceuticals (IONS -$1.27) Mesoblast (MESO -$0.03)> 1 MISS < Maintaining SELL: Biostage (BSTG +$0.10 with 1,501 (the stock “pumping” continues)>
Key metrics:
- Sector volume was LOW with 3 of the 9-upside having higher than the 3-month average volume with the increased volume of 9 of 25-downside having higher than the 3-month average volume;
- Thursday’s percentage (%) of the 9-upside were +0.40% (RENE.L) to +7.04% (BSTG) while the 25-downside ranges from -0.32% (MESO) to-13.49% (CLBS);
There are clear winners — and losers — heading into the first month of 2021.
Jumping with share pricing momentum:
- BioLife Solutions (BLFS), Sage Therapeutics (SAGE), ReNeuron (RENE.L), Vericel (VCEL), Solid bioscience (SLDB) to name 5 of the 9 inclining of the 35 covered
Hammered in today’s market:
- Fate Therapeutics (FATE), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY), to name 5 of the 25 declining of the 35 covered
Thursday’s (9 of 9) incliners:
- BioLife Solutions (BLFS +$2.13 after Wednesday’s -$0.52 and Tuesday’s +$0.79);
- Sage Therapeutics (SAGE +$1.23 after Wednesday’s +$1.66 and Tuesday’s -$1.83);
- ReNeuron (RENE.L +$0.50 after Wednesday’s -$9.50 and Tuesday’s flat);
- Vericel (VCEL$0.42 after Wednesday’s +$0.75);
- Solid biosciences (SLDB +$0.32);
- Brainstorm Cell therapeutics (BCLI +$0.24);
- Chinook Therapeutics (KDNY +$0.19 after Wednesday’s -$0.48);
- Biostage (BSTG +$0.10);
- Applied Genetic Technologies (AGTC +$0.02);
Thursday’s (10 of 25) decliners:
- Fate Therapeutics (FATE -$9.34 after Wednesday’s -$5.30 and Tuesday’s +$0.72);
- Editas Medicine (EDIT -$7.97);
- Intellia Therapeutics (NTLA -$7.97 after Wednesday’s -$3.12 and Tuesday’s +$1.79);
- CRISPR Therapeutics (CRSP -$4.67 after Wednesday’s -$8.52 and Tuesday’s -$1.59);
- Alnylam Pharmaceuticals (ALNY -$4.22 after Wednesday’s +$2.56 and Tuesday’s +$2.05);
- Ultragenyx (RARE -$2.06 after Wednesday’s -$3.72 and Tuesday’s +$0.90);
- Regenxbio (RGNX -$1.94 after Wednesday’s -$3.22 and Tuesday’s -$0.49);
- Cellectis SA (CLLS -$1.47);
- Ionis Pharmaceuticals (IONS -$1.27 after Wednesday’s +$1.51 and Tuesday’s -0.25);
- bluebird bio (BLUE -$1.04 after Wednesday’s -$1.63 and Tuesday’s -$1.02);
Closing 1 -Stemline Therapeutics (STML – acquired)
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Thursday, the IBB closed down -0.89% and XBI closed down -2.17%
- Wednesday, the IBB closed up +0.10% and XBI closed down -0.06%
- Tuesday, the IBB closed up +1.93% and XBI closed up +1.64%
- Monday was holiday
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Thursday was down -0.26 points or -1.20% at 21.32
- Wednesday was down -1.66 points or -7.14% at 21.58
- Tuesday was down -1.10 points or -4.52% at 23.24
- Monday was a holiday
Upside volume:
- Thursday: 3 out of the 9-upside had higher than the 3-month average volume;
- Wednesday: 5 out of the 16-upside had higher than the 3-month average volume;
- Tuesday: 5 out of the 18-upside had higher than the 3-month average volume;
- Monday was a holiday
Downside volume:
- Thursday: 9 out of the 25-downside had higher than the 3-month average volume;
- Wednesday: 6 out of the 18-downside had higher than the 3-month average volume;
- Tuesday: 7 out of the 14-downside had higher than the 3-month average volume;
- Monday was a holiday
Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing
- Thursday’s percentage (%) of the 9-upside were +0.40% (RENE.L) to +7.04% (BSTG) while the 25-downside ranges from -0.32% (MESO) to-13.49% (CLBS);
- Wednesday’s percentage (%) of the 16-upside were +0.25% (PSTI) to +77.30% (CLBS) while the 18-downside ranges from -0.17% (SLDB) to-10.20% (VSTM);
- Tuesday’s percentage (%) of the 18-upside were +0.63% (FATE) to +15.57% (BSTG) while the 14-downside ranges from -0.07% (KDNY) to -6.64% (SLDB);
- Monday was a holiday
January, the 1st month of Q1 …
Thursday closed negative with 9 advancers, 25 decliners and 1 acquired
Wednesday closed negative with 18 advancers, 16 decliners and 1 acquired
Tuesday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired
Monday (1/18) was a holiday
Friday closed negative with 10 advancers, 24 decliners and 1 acquired
Thursday closed positive with 27 advancers, 7 decliners and 1 acquired
Wednesday closed positive with 10 advancers, 21 decliners and 4 flats
Tuesday closed positive with 21 advancers, 13 decliners and 1 flat
Monday (1/11) closed negative with 13 advancers, 20 decliners and 2 flats
Friday closed negative with 16 advancers, 18 decliners and 1 flat
Thursday closed positive with 31 advancers, 2 decliners and 2 flats
Wednesday closed positive with 22 advancers, 12 decliners and 1 flat
Tuesday closed positive with 19 advancers, 14 decliners and 2 flats
Monday (1/4) closed positive with 26 advancers, 7 decliners and 2 flats
The Bottom Line: I see the pace of vaccinations as a key driver of equities through Q1-Q2/2021 …
There is STILL a short-term tone in the sector – “our’ universe of RegMed, stem, cell and gene therapy equities.
Wednesday’s negative close “might have less to do with the inauguration than it does with earning’s season about to begin and with investors taking advantage of recent performance to lighten-up on appreciators”.
To make money in this sector, one has to know when to get out and which individual equity you should stay in!
Forewarned … Earnings LPS (los-per-share) season is coming quickly – my advice, trim and skim!!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
